Skip to main content
Erschienen in: Annals of Surgical Oncology 9/2020

24.03.2020 | Gastrointestinal Oncology

Intraoperative Surrogate Indicators of Gastric Cancer Patients’ Long-Term Prognosis: The Number of Lymph Nodes Examined Relates to the Lymph Node Noncompliance Rate

verfasst von: Guang-Tan Lin, MD, Qi-Yue Chen, MD, Qing Zhong, MD, Chao-Hui Zheng, MD, Ping Li, PhD, Jian-Wei Xie, PhD, Jia-Bin Wang, PhD, Jian-Xian Lin, MD, Jun Lu, MD, Chang-Ming Huang, MD, PhD

Erschienen in: Annals of Surgical Oncology | Ausgabe 9/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

The number of examined lymph nodes (ExLNs) and the rate of lymph node (LN) noncompliance are two independent indicators for evaluating the oncological efficacy for radical gastric cancer (GC) surgery. There are no studies to prove the relationship between these two indicators and their influence on the long-term prognosis of GC patients.

Methods

The clinicopathological data of 1872 patients with radical GC resection with pathological stage pT2-4N0-3M0 from June 2007 to June 2013 were retrospectively analyzed. Noncompliance was defined as patients with more than one or more LN stations absence as described in the protocol for lymphadenectomy in the Japanese Gastric Cancer Association.

Results

Among 1872 patients, 941 (50.3%) had complete LN compliance, 469 (25.1%) had minor LN noncompliance, and 462 (24.6%) had major LN noncompliance. Logistic regression analysis showed that cT staging and ExLNs were independent risk factors for LN noncompliance. In the whole group, Kaplan–Meier survival curve elucidated that overall survival (OS) differences of ExLNs ≤ 25 and ExLNs > 25 were statistically significant (p < 0.001). Stratified analysis of LN noncompliance elucidated no statistically significant difference in OS of these two group. Multivariate COX regression analysis suggested that LN noncompliance was an independent prognostic factor for OS, whereas ExLNs was no longer an independent prognostic factor for OS.

Conclusions

The increase number of ExLNs can improve the OS of GC patients, which depends on the decrease of LN noncompliance rate. As surrogate indicators for long-term prognosis of GC patients, LN noncompliance rate was better than ExLNs number.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.PubMed Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.PubMed
2.
Zurück zum Zitat Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.PubMed Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.PubMed
3.
Zurück zum Zitat Dikken JL, Jan-sen EP, Cats A, et al. Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer. J Clin Oncol. 2010;28(14):2430–6.PubMed Dikken JL, Jan-sen EP, Cats A, et al. Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer. J Clin Oncol. 2010;28(14):2430–6.PubMed
4.
Zurück zum Zitat Dicken BJ, Bigam DL, Cass C, et al. Gastric adenocarcinoma: review and considerations for future directions. Ann Surg. 2005;241(1):27–39.PubMedPubMedCentral Dicken BJ, Bigam DL, Cass C, et al. Gastric adenocarcinoma: review and considerations for future directions. Ann Surg. 2005;241(1):27–39.PubMedPubMedCentral
5.
Zurück zum Zitat Jackson C, Cunningham D, Oliveira J. Gastric cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20(Suppl 4):34–6.PubMed Jackson C, Cunningham D, Oliveira J. Gastric cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20(Suppl 4):34–6.PubMed
6.
Zurück zum Zitat Orditura M, Galizia G, Sforza V, et al. Treatment of gastric cancer. World J Gastroenterol. 2014;20(7):1635–49.PubMedPubMedCentral Orditura M, Galizia G, Sforza V, et al. Treatment of gastric cancer. World J Gastroenterol. 2014;20(7):1635–49.PubMedPubMedCentral
7.
Zurück zum Zitat Cuschieri A, Weeden S, Fielding J, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer. 1999;79(9–10):1522–30.PubMed Cuschieri A, Weeden S, Fielding J, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer. 1999;79(9–10):1522–30.PubMed
8.
Zurück zum Zitat Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med. 1985;312(25):1604–8.PubMed Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med. 1985;312(25):1604–8.PubMed
9.
Zurück zum Zitat Songun I, Putter H, Kranenbarg EM, et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010;11(5):439–49.PubMed Songun I, Putter H, Kranenbarg EM, et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010;11(5):439–49.PubMed
10.
Zurück zum Zitat Fleming ID, Cooper JS, Henson DE, et al. American joint committee on cancer staging manual (5th edn). Philadelphia: Raven and Lippincott; 1997. Fleming ID, Cooper JS, Henson DE, et al. American joint committee on cancer staging manual (5th edn). Philadelphia: Raven and Lippincott; 1997.
11.
Zurück zum Zitat Karpeh MS, Leon L, Klimstra D, et al. Lymph node staging in gastric cancer: is location more important than number? An analysis of 1,038 patients. Ann Surg. 2000;232(3):362–71.PubMedPubMedCentral Karpeh MS, Leon L, Klimstra D, et al. Lymph node staging in gastric cancer: is location more important than number? An analysis of 1,038 patients. Ann Surg. 2000;232(3):362–71.PubMedPubMedCentral
12.
Zurück zum Zitat Siewert JR, Böttcher K, Stein HJ, et al. Relevant prognostic factors in gastric cancer: Ten-year results of the German Gastric Cancer Study. Ann Surg. 1998;228(4):449–61.PubMedPubMedCentral Siewert JR, Böttcher K, Stein HJ, et al. Relevant prognostic factors in gastric cancer: Ten-year results of the German Gastric Cancer Study. Ann Surg. 1998;228(4):449–61.PubMedPubMedCentral
13.
Zurück zum Zitat Liu KJ, Loewen M, Atten MJ, et al. The survival of stage III gastric cancer patients is affected by the number of lymph nodes removed. Surgery. 2003;134(4):639–44, (discussion 644–6).PubMed Liu KJ, Loewen M, Atten MJ, et al. The survival of stage III gastric cancer patients is affected by the number of lymph nodes removed. Surgery. 2003;134(4):639–44, (discussion 644–6).PubMed
14.
Zurück zum Zitat Lee HK, Yang HK, Kim WH, et al. Influence of the number of lymph nodes examined on staging of gastric cancer. Br J Surg. 2001;88(10):1408–12.PubMed Lee HK, Yang HK, Kim WH, et al. Influence of the number of lymph nodes examined on staging of gastric cancer. Br J Surg. 2001;88(10):1408–12.PubMed
15.
Zurück zum Zitat Bunt AM, Hogendoorn PC, van de Velde CJ, et al. Lymph node staging standards in gastric cancer. J Clin Oncol. 1995;13(9):2309–16.PubMed Bunt AM, Hogendoorn PC, van de Velde CJ, et al. Lymph node staging standards in gastric cancer. J Clin Oncol. 1995;13(9):2309–16.PubMed
16.
Zurück zum Zitat Noda N, Sasako M, Yamaguchi N, et al. Ignoring small lymph nodes can be a major cause of staging error in gastric cancer. Br J Surg. 1998;85(6):831–4.PubMed Noda N, Sasako M, Yamaguchi N, et al. Ignoring small lymph nodes can be a major cause of staging error in gastric cancer. Br J Surg. 1998;85(6):831–4.PubMed
17.
Zurück zum Zitat Bonenkamp JJ, Songun I, Hermans J, et al. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet. 1995;345(8952):745–8.PubMed Bonenkamp JJ, Songun I, Hermans J, et al. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet. 1995;345(8952):745–8.PubMed
18.
Zurück zum Zitat Bonenkamp JJ, Hermans J, Sasako M, et al. Extended lymph-node dissection for gastric cancer. N Engl J Med. 1999;340(12):908–14.PubMed Bonenkamp JJ, Hermans J, Sasako M, et al. Extended lymph-node dissection for gastric cancer. N Engl J Med. 1999;340(12):908–14.PubMed
19.
Zurück zum Zitat Bonenkamp JJ, Hermans J, Sasako M, et al. Quality control of lymph node dissection in the Dutch randomized trial of D1 and D2 lymph node dissection for gastric cancer. Gastric Cancer. 1998;1(2):152–9.PubMed Bonenkamp JJ, Hermans J, Sasako M, et al. Quality control of lymph node dissection in the Dutch randomized trial of D1 and D2 lymph node dissection for gastric cancer. Gastric Cancer. 1998;1(2):152–9.PubMed
20.
Zurück zum Zitat Claassen YHM, de Steur WO, Hartgrink HH, et al. Surgicopathological Quality Control and Protocol Adherence to Lymphadenectomy in the CRITICS Gastric Cancer Trial. Ann Surg. 2018;268(6):1008–13.PubMed Claassen YHM, de Steur WO, Hartgrink HH, et al. Surgicopathological Quality Control and Protocol Adherence to Lymphadenectomy in the CRITICS Gastric Cancer Trial. Ann Surg. 2018;268(6):1008–13.PubMed
21.
Zurück zum Zitat Claassen YHM, van Sandick JW, Hartgrink HH, et al. Association between hospital volume and quality of gastric cancer surgery in the CRITICS trial. Br J Surg. 2018;105(6):728–35.PubMed Claassen YHM, van Sandick JW, Hartgrink HH, et al. Association between hospital volume and quality of gastric cancer surgery in the CRITICS trial. Br J Surg. 2018;105(6):728–35.PubMed
22.
Zurück zum Zitat Park YK, Yoon HM, Kim YW, et al. Laparoscopy-assisted versus open D2 distal gastrectomy for advanced gastric cancer: results from a randomized Phase II Multicenter Clinical Trial (COACT 1001). Ann Surg. 2018;267(4):638–45.PubMed Park YK, Yoon HM, Kim YW, et al. Laparoscopy-assisted versus open D2 distal gastrectomy for advanced gastric cancer: results from a randomized Phase II Multicenter Clinical Trial (COACT 1001). Ann Surg. 2018;267(4):638–45.PubMed
23.
Zurück zum Zitat Chen QY, Zhong Q, Liu ZY, et al. Does noncompliance in lymph node dissection affect oncological efficacy in gastric cancer patients undergoing radical gastrectomy? Ann Surg Oncol. 2019;26(6):1759–71.PubMed Chen QY, Zhong Q, Liu ZY, et al. Does noncompliance in lymph node dissection affect oncological efficacy in gastric cancer patients undergoing radical gastrectomy? Ann Surg Oncol. 2019;26(6):1759–71.PubMed
24.
Zurück zum Zitat Lin GT, Chen QY, Zheng CH, et al. Lymph node noncompliance affects the long-term prognosis of patients with gastric cancer after laparoscopic total gastrectomy. J Gastrointest Surg. 2019;24(3):540–50.PubMed Lin GT, Chen QY, Zheng CH, et al. Lymph node noncompliance affects the long-term prognosis of patients with gastric cancer after laparoscopic total gastrectomy. J Gastrointest Surg. 2019;24(3):540–50.PubMed
25.
Zurück zum Zitat Chen Q-Y, Lin G-T, Zhong Q, et al. Laparoscopic total gastrectomy for upper-middle advanced gastric cancer: analysis based on lymph node noncompliance. Gastric Cancer. 2020;23(1):184–94.PubMed Chen Q-Y, Lin G-T, Zhong Q, et al. Laparoscopic total gastrectomy for upper-middle advanced gastric cancer: analysis based on lymph node noncompliance. Gastric Cancer. 2020;23(1):184–94.PubMed
26.
Zurück zum Zitat Baxter NN, Tuttle TM. Inadequacy of lymph node staging in gastric cancer patients: a population-based study. Ann Surg Oncol. 2005;12(12):981–7.PubMed Baxter NN, Tuttle TM. Inadequacy of lymph node staging in gastric cancer patients: a population-based study. Ann Surg Oncol. 2005;12(12):981–7.PubMed
27.
Zurück zum Zitat Coburn NG, Swallow CJ, Kiss A, et al. Significant regional variation in adequacy of lymph node assessment and survival in gastric cancer. Cancer. 2006;107(9):2143-51.PubMed Coburn NG, Swallow CJ, Kiss A, et al. Significant regional variation in adequacy of lymph node assessment and survival in gastric cancer. Cancer. 2006;107(9):2143-51.PubMed
28.
Zurück zum Zitat Kulig J, Sierzega M, Kolodziejczyk P, et al. Ratio of metastatic to resected lymph nodes for prediction of survival in patients with inadequately staged gastric cancer. Br J Surg. 2009;96(8):910–18.PubMed Kulig J, Sierzega M, Kolodziejczyk P, et al. Ratio of metastatic to resected lymph nodes for prediction of survival in patients with inadequately staged gastric cancer. Br J Surg. 2009;96(8):910–18.PubMed
29.
Zurück zum Zitat Nitti D, Marchet A, Olivieri M, et al. Ratio between metastatic and examined lymph nodes is an independent prognostic factor after D2 resection for gastric cancer: analysis of a large European monoinstitutional experience. Ann Surg Oncol 2003;10(9):1077–85.PubMed Nitti D, Marchet A, Olivieri M, et al. Ratio between metastatic and examined lymph nodes is an independent prognostic factor after D2 resection for gastric cancer: analysis of a large European monoinstitutional experience. Ann Surg Oncol 2003;10(9):1077–85.PubMed
30.
Zurück zum Zitat Liu YY, Fang WL, Wang F, et al. Does a higher cutoff value of lymph node retrieval substantially improve survival in patients with advanced gastric cancer? Time to embrace a new digit. Oncologist. 2017; 22(1):97–106.PubMed Liu YY, Fang WL, Wang F, et al. Does a higher cutoff value of lymph node retrieval substantially improve survival in patients with advanced gastric cancer? Time to embrace a new digit. Oncologist. 2017; 22(1):97–106.PubMed
31.
Zurück zum Zitat Smith DD, Schwarz RR, Schwarz RE. Impact of total lymph node count on staging and survival after gastrectomy for gastric cancer: data from a large US-population database. J Clin Oncol. 2005;23(28):7114–24.PubMed Smith DD, Schwarz RR, Schwarz RE. Impact of total lymph node count on staging and survival after gastrectomy for gastric cancer: data from a large US-population database. J Clin Oncol. 2005;23(28):7114–24.PubMed
32.
Zurück zum Zitat Huang CM, Lin JX, Zheng CH, et al. Impact of the number of dissected lymph nodes on survival for gastric cancer after distal subtotal gastrectomy. Gastroenterol Res Pract. 2011;2011:476014.PubMedPubMedCentral Huang CM, Lin JX, Zheng CH, et al. Impact of the number of dissected lymph nodes on survival for gastric cancer after distal subtotal gastrectomy. Gastroenterol Res Pract. 2011;2011:476014.PubMedPubMedCentral
33.
Zurück zum Zitat Seevaratnam R, Bocicariu A, Cardoso R, et al. How many lymph nodes should be assessed in patients with gastric cancer? A systematic review. Gastric Cancer. 2012;15(Suppl 1):S70–88.PubMed Seevaratnam R, Bocicariu A, Cardoso R, et al. How many lymph nodes should be assessed in patients with gastric cancer? A systematic review. Gastric Cancer. 2012;15(Suppl 1):S70–88.PubMed
34.
Zurück zum Zitat Schwarz RE, Smith DD. Clinical impact of lymphadenectomy extent in resectable gastric cancer of advanced stage. Ann Surg Oncol. 2007;14(2):317–28.PubMed Schwarz RE, Smith DD. Clinical impact of lymphadenectomy extent in resectable gastric cancer of advanced stage. Ann Surg Oncol. 2007;14(2):317–28.PubMed
35.
Zurück zum Zitat Baiocchi GL, Tiberio GA, Minicozzi AM, et al. A multicentric Western analysis of prognostic factors in advanced, node-negative gastric cancer patients. Ann Surg. 2010;252(1):70–3.PubMed Baiocchi GL, Tiberio GA, Minicozzi AM, et al. A multicentric Western analysis of prognostic factors in advanced, node-negative gastric cancer patients. Ann Surg. 2010;252(1):70–3.PubMed
36.
Zurück zum Zitat Cuschieri A, Weeden S, Fielding J, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Br J Cancer. 1999;79(9):1522-30.PubMedPubMedCentral Cuschieri A, Weeden S, Fielding J, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Br J Cancer. 1999;79(9):1522-30.PubMedPubMedCentral
37.
Zurück zum Zitat de Steur WO, Hartgrink HH, Dikken JL, et al. Quality control of lymph node dissection in the Dutch Gastric Cancer Trial. Br J Surg. 2015;102(11):1388–93.PubMed de Steur WO, Hartgrink HH, Dikken JL, et al. Quality control of lymph node dissection in the Dutch Gastric Cancer Trial. Br J Surg. 2015;102(11):1388–93.PubMed
38.
Zurück zum Zitat Giuliani A, Caporale A, Corona M, et al. Lymphadenectomy in gastric cancer: influence on prognosis of lymph node count. J Exp Clin Cancer Res. 2004;23(2):215–24.PubMed Giuliani A, Caporale A, Corona M, et al. Lymphadenectomy in gastric cancer: influence on prognosis of lymph node count. J Exp Clin Cancer Res. 2004;23(2):215–24.PubMed
39.
Zurück zum Zitat Liu C, Lu Y, Jun Z, et al. Impact of total retrieved lymph nodes on staging and survival of patients with gastric cancer invading the subserosa. Surg Oncol. 2009;18(4):379–84.PubMed Liu C, Lu Y, Jun Z, et al. Impact of total retrieved lymph nodes on staging and survival of patients with gastric cancer invading the subserosa. Surg Oncol. 2009;18(4):379–84.PubMed
40.
Zurück zum Zitat Marchet A, Mocellin S, Ambrosi A, et al. The ratio between metastatic and examined lymph nodes (N ratio) is an independent prognostic factor in gastric cancer regardless of the type of lymphadenectomy: results from an Italian multicentric study in 1853 patients. Ann Surg. 2007;245(4):543–52.PubMedPubMedCentral Marchet A, Mocellin S, Ambrosi A, et al. The ratio between metastatic and examined lymph nodes (N ratio) is an independent prognostic factor in gastric cancer regardless of the type of lymphadenectomy: results from an Italian multicentric study in 1853 patients. Ann Surg. 2007;245(4):543–52.PubMedPubMedCentral
41.
Zurück zum Zitat Bouvier AM, Haas O, Piard F, et al. How many nodes must be examined to accurately stage gastric carcinomas? Results from a population based study. Cancer. 2002;94(11):2862–6.PubMed Bouvier AM, Haas O, Piard F, et al. How many nodes must be examined to accurately stage gastric carcinomas? Results from a population based study. Cancer. 2002;94(11):2862–6.PubMed
42.
Zurück zum Zitat Bruno L, Nesi G, Montinaro F, et al. Clinicopathologic characteristics and outcome indicators in node-negative gastric cancer. J Surg Oncol. 2000;74(1):30–2.PubMed Bruno L, Nesi G, Montinaro F, et al. Clinicopathologic characteristics and outcome indicators in node-negative gastric cancer. J Surg Oncol. 2000;74(1):30–2.PubMed
43.
Zurück zum Zitat Deng JY, Liang H, Sun D, et al. Outcome in relation to numbers of nodes harvested in lymph node-positive gastric cancer. Eur J Surg Oncol. 2009;35(8):814–9.PubMed Deng JY, Liang H, Sun D, et al. Outcome in relation to numbers of nodes harvested in lymph node-positive gastric cancer. Eur J Surg Oncol. 2009;35(8):814–9.PubMed
44.
Zurück zum Zitat Huang CM, Lin JX, Zheng CH, et al. Prognostic impact of dissected lymph node count on patients with node-negative gastric cancer. World J Gastroenterol. 2009;15(31):3926–30.PubMedPubMedCentral Huang CM, Lin JX, Zheng CH, et al. Prognostic impact of dissected lymph node count on patients with node-negative gastric cancer. World J Gastroenterol. 2009;15(31):3926–30.PubMedPubMedCentral
45.
Zurück zum Zitat Maruyama K, Okabayashi K, Kinoshita T. Progress in gastric cancer surgery in Japan and its limits of radicality. World J Surg. 1987;11(4):418–25.PubMed Maruyama K, Okabayashi K, Kinoshita T. Progress in gastric cancer surgery in Japan and its limits of radicality. World J Surg. 1987;11(4):418–25.PubMed
46.
Zurück zum Zitat Wagner PK, Ramaswamy A, Rüschoff J, et al. Lymph node counts in the upper abdomen: anatomical basis for lymphadenectomy in gastric cancer. Br J Surg. 1991;78(7):825–7.PubMed Wagner PK, Ramaswamy A, Rüschoff J, et al. Lymph node counts in the upper abdomen: anatomical basis for lymphadenectomy in gastric cancer. Br J Surg. 1991;78(7):825–7.PubMed
Metadaten
Titel
Intraoperative Surrogate Indicators of Gastric Cancer Patients’ Long-Term Prognosis: The Number of Lymph Nodes Examined Relates to the Lymph Node Noncompliance Rate
verfasst von
Guang-Tan Lin, MD
Qi-Yue Chen, MD
Qing Zhong, MD
Chao-Hui Zheng, MD
Ping Li, PhD
Jian-Wei Xie, PhD
Jia-Bin Wang, PhD
Jian-Xian Lin, MD
Jun Lu, MD
Chang-Ming Huang, MD, PhD
Publikationsdatum
24.03.2020
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 9/2020
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-020-08387-9

Weitere Artikel der Ausgabe 9/2020

Annals of Surgical Oncology 9/2020 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.